DaVita opens PI facility for kidney research

By Natalie Morrison

- Last updated on GMT

The renal medulla
The renal medulla

Related tags Us food and drug administration

DaVita Clinical Research has opened a Phase I facility focussed on kidney research in a bid to meet a “growing demand” for renal trials.

The centre – a 35,000 sq ft 80-bed amenity based in St.Anthony hospital campus in Colorado, US – will help sponsors assess how drugs pass through the kidney or how they interact with the liver.

The move extends DaVita’s total number of beds in North America to 122, and means the clinical research organisation (CRO) can for the first time recruit healthy volunteers as well as patient populations.

Speaking to Outsourcing-Pharma.com, VP of commercial development Kevin Goudreau said the expansion was a response to a rise in the number of renal trials as a result of increasing regulatory pressures.

“The regulators are putting more focus on understanding exactly how the drug works in vitro and as a result are putting more focus on this area,” ​he said.

VP of clinical services Amy Young added that 80 per cent or more of studies going through the US Food and Drug Administration (FDA) approval process at present are required to look at toxicity activity in the kidney, and an increasing focus on hepatic trials.

“Basically, there is an increase in pressure to do more early on in clinical trials,”​ she told us, adding that more than 90 per cent of trials need renal or hepatic data.

Niche offering

Goudreau admitted that the decision to open such a specified facility may seem unusual in the present climate, with the industry leaning towards bigger strategic deals rather than more niche offerings.

However he said it is those strategic deals that provide it with a large chunk of business.

“We don’t only go directly to pharma companies, we build relationships with CROs who have strategic relationships with these companies. When they need this sort of specialised activity, they come to us,”​ he said.

He added that renal and hepatic expertise is only part of the attraction for those looking to outsource, as patient access is also a big boon.

Young added: “It takes a different level of staff and expertise to manage these kind of trials. Finding the right patient population is exactly what companies are looking for, rather than cost.”

Goudreau however said that cost still does come into the equation, but that supply and demand for patients means that getting a bargain is not necessarily as important as in other service arenas.

“Any of the big partnership models forged between sponsors and CROs have really focussed on driving costs down over the past five years, but​ it’s crucial to have access to patients and often companies are all vying for the same patient,” ​he said. “Sometimes you have to beat five or more other companies to get access.”

Related news

Show more

Related products

show more

Drug Solubility and the Need for Speed

Drug Solubility and the Need for Speed

Lonza Small Molecules | 28-Mar-2023 | Technical / White Paper

A growing number of new chemical entities are highly insoluble, leading to problems with bioavailability. Drug manufacturers therefore have to find ways...

Are You Prepared to Meet the New FDA Guidelines?

Are You Prepared to Meet the New FDA Guidelines?

Elligo Health Research® | 23-Mar-2023 | Insight Guide

On April 15, 2022, the U.S. Food and Drug Administration issued a new draft guidance to clinical research sponsors on creating a plan to enroll more participants...

ODM and CDASH in CRF design

ODM and CDASH in CRF design

Formedix | 10-Mar-2023 | Technical / White Paper

The lesser-known Operational Data Model (ODM) standard is often overlooked as it's not required by any regulators. So, why should you be interested...

How Sponsors Reduce Chaos in Decentralized Trials

How Sponsors Reduce Chaos in Decentralized Trials

Florence Healthcare | 08-Mar-2023 | Insight Guide

89% of research sponsors currently use and expect to continue the use of decentralized technologies and methods, according to our state of the industry...

Related suppliers

Follow us


View more